Estriol cream is a topical hormone therapy used primarily to treat vaginal dryness, tissue thinning, and discomfort caused by declining estrogen levels during and after menopause. It contains estriol, one of the three estrogens the body naturally produces, and it works locally on the tissues where it’s applied rather than flooding the entire body with hormones. In the United States, estriol cream is not FDA-approved and is typically available only through compounding pharmacies, though it is widely prescribed in Europe and other countries.
Vaginal Atrophy and Dryness
The most common reason women use estriol cream is to relieve the symptoms of vaginal atrophy, a condition where vaginal tissues become thinner, drier, and less elastic after menopause. This happens because estrogen is responsible for keeping the vaginal lining thick and well-lubricated. When estrogen drops, the tissue shrinks, moisture decreases, and everyday activities like sitting, exercising, or having sex can become uncomfortable or painful.
Estriol cream works by restoring thickness to the vaginal lining and increasing moisture production. Clinical studies using an ultralow-dose estriol gel found that vaginal dryness scores dropped significantly within just 7 days of starting treatment, with even greater improvement by day 14. That rapid timeline is one reason many women prefer topical estriol to oral hormone therapy for localized symptoms.
Restoring Vaginal Bacterial Balance
A healthy vagina relies on a population of beneficial bacteria, primarily lactobacilli, that produce lactic acid and keep the pH below 4.5. This acidic environment suppresses the growth of harmful organisms. After menopause, lower estrogen levels cause the vaginal lining to thin, which reduces the glycogen that lactobacilli feed on. Without that fuel, lactobacilli decline, pH rises, and infections become more likely.
Estriol cream helps reverse this chain of events. By rebuilding the vaginal epithelium, it restores the glycogen supply that lactobacilli need to thrive. Studies combining low-dose estriol (0.03 mg) with lactobacillus supplements showed significant improvements in what researchers call the “Normal Flora Index,” a composite score based on lactobacillus counts, pathogen counts, pH, and immune cell presence. The improvements held for four to six weeks after treatment ended. This combination approach has been used in both premenopausal and postmenopausal women to restore vaginal flora after antibiotic treatment or antifungal therapy.
Preventing Recurrent Urinary Tract Infections
One of the most practical uses of vaginal estriol cream is reducing the frequency of urinary tract infections in postmenopausal women. The vagina and urethra share embryonic tissue origins, so when vaginal tissues thin from low estrogen, the urethral tissues do too. This makes it easier for bacteria to colonize the urinary tract.
A large retrospective study of 5,600 women with low estrogen who were prescribed vaginal estrogen for recurrent UTIs found that infection frequency dropped by more than 50%, falling from an average of 3.9 UTIs per year to 1.8. After starting treatment, 55% of patients had one or fewer UTIs in the following year, and about 31% had none at all. For women who have been cycling through repeated rounds of antibiotics, this can be a significant quality-of-life improvement.
Skin and Anti-Aging Applications
Some women use estriol cream topically on the face or body to counteract the skin changes that come with menopause. Estrogen plays a direct role in collagen production, and collagen loss accelerates sharply after menopause, contributing to thinner skin, wrinkles, and reduced elasticity.
A pilot study of postmenopausal women using topical estrogen on facial skin found that both the outer skin layer and the deeper dermal layer became measurably thicker after treatment. Collagen content increased significantly after 16 weeks, and importantly, the topical application did not raise blood estrogen levels to a statistically significant degree. This suggests the effects remained largely local. While this is a promising area, topical estriol for skin aging is considered off-label, and standardized formulations for this purpose are not widely available.
How Estriol Differs From Stronger Estrogens
Your body produces three types of estrogen: estradiol (the strongest and most abundant before menopause), estrone, and estriol (the weakest). Estriol binds to estrogen receptors at a similar speed as estradiol, but it detaches about ten times faster. This means its effects are shorter-lived and less potent at the cellular level. In laboratory measurements, estriol’s binding affinity to estrogen receptors is roughly 14 times weaker than estradiol’s.
This weaker activity is actually the point for many applications. Because estriol stimulates tissues enough to relieve local symptoms but clears quickly, it carries a lower risk of the systemic effects associated with stronger estrogens. It also shows a slight preference for one of the two estrogen receptor types (beta over alpha), which may contribute to its tissue-specific effects in the vagina and urinary tract.
Systemic Absorption and Safety
A common concern with any hormone cream is how much gets absorbed into the bloodstream. A prospective study tracking estriol blood levels in both new and long-term users of vaginal estriol cream found that 87% of women had 12-hour estriol levels below 100 pmol/L, a reassuringly low threshold. New users started with levels below 5 pmol/L, and after 12 weeks of use, the median level was 22.8 pmol/L. Long-term users actually had slightly lower median levels (15.1 pmol/L), suggesting the body doesn’t accumulate estriol over time.
A small number of women in the study did show spikes above 100 pmol/L, which means absorption varies from person to person. Still, the overall picture supports that vaginal estriol cream acts mostly locally.
Does It Require Progesterone Protection?
With oral or patch-based estrogen therapy, women who still have a uterus typically need to take a progestogen alongside estrogen to prevent the uterine lining from thickening abnormally, a condition called endometrial hyperplasia. One important question with estriol cream is whether the same precaution applies.
A systematic evidence review of low-dose vaginal estrogens concluded that the data do not support an increased risk of endometrial hyperplasia or cancer with low-dose, unopposed vaginal estrogen use. This means most women using vaginal estriol cream at standard low doses do not need to add a progestogen. The review did note, however, that longer-term real-world data would strengthen this conclusion.
Availability and Formulations
In the United States, estriol is not available as an FDA-approved product. Women who use it obtain it through compounding pharmacies, where it is prepared in custom concentrations. Common formulations range from 0.025% (0.25 mg per gram of cream) up to 1% (10 mg per gram), and stability testing has shown these preparations remain effective for at least six months at room temperature or refrigerated. Because compounded medications are not standardized the way commercial drugs are, the quality and consistency can vary between pharmacies.
In Europe, several commercially manufactured estriol products are approved and widely available, including vaginal creams, gels, and pessaries at doses as low as 0.005%. The ultralow-dose formulations have generated particular interest because they appear to relieve symptoms effectively while minimizing even the small amount of systemic absorption seen with standard doses.
Other Uses Under Investigation
Beyond vaginal and skin health, researchers are exploring estriol for several other conditions. These include relieving menstrual migraines, improving cognitive function, treating postpartum depression, and managing inflammatory neurological conditions like multiple sclerosis. All of these remain off-label and investigational, without enough clinical evidence yet to support routine use.